Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
{{output}}
Background: Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical costs o... ...
